Brief: Carsgen Therapeutics Sees Net Loss Not More Than RMB80 Million In HY
25/07/2025 02:38
July 25 (Reuters) - CARsgen Therapeutics 2171.HK: SEES NET LOSS NOT MORE THAN RMB80 MILLION IN HY REDUCTION IN LOSS DUE TO CT053 COMMERCIALIZATION AND REDUCED RESEARCH AND DEVELOPMENT Further company coverage: 2171.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer